Lang AE and Lozano AM: Parkinson’s disease. First of two parts. N Engl J Med. 339:1044–1053. 1998.

Anandhan A, Essa MM and Manivasagam T: Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson’s disease. Neurotox Res. 23:166–173. 2013.PubMed/NCBI

Barnum CJ and Tansey MG: Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson’s disease? Curr Neurol Neurosci Rep. 12:350–358. 2012.PubMed/NCBI

Sekiyama K, Sugama S, Fujita M, et al: Neuroinflammation in Parkinson’s disease and related disorders: A lesson from genetically manipulated mouse models of α-synucleinopathies. Parkinsons Dis. 2012:2717322012.

Hirsch EC, Vyas S and Hunot S: Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord. 18(Suppl 1): S210–S212. 2012.

Khan MM, Kempuraj D, Thangavel R and Zaheer A: Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol. Neurochem Int. 62:379–388. 2013. View Article : Google Scholar : PubMed/NCBI

Ghosh A, Kanthasamy A, Joseph J, et al: Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson’s disease. J Neuroinflammation. 9:2412012.PubMed/NCBI

Yan J, Xu Y, Zhu C, et al: Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS One. 6:e209452011. View Article : Google Scholar

Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE and Pahan K: Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson’s disease. J Neurosci. 29:13543–13556. 2009.PubMed/NCBI

Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J and Höglinger GU: Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol. 238:183–191. 2012. View Article : Google Scholar

Dutta G, Barber DS, Zhang P, Doperalski NJ and Liu B: Involvement of dopaminergic neuronal cystatin C in neuronal injury-induced microglial activation and neurotoxicity. J Neurochem. 122:752–763. 2012. View Article : Google Scholar : PubMed/NCBI

Long-Smith CM, Sullivan AM and Nolan YM: The influence of microglia on the pathogenesis of Parkinson’s disease. Prog Neurobiol. 89:277–287. 2009.

Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B and Hong JS: Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci. 20:6309–6316. 2000.PubMed/NCBI

Whitton PS: Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br J Pharmacol. 150:963–976. 2007.

Crotty S, Fitzgerald P, Tuohy E, et al: Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson’s disease. Eur J Neurosci. 27:294–300. 2008.PubMed/NCBI

Mirza B, Hadberg H, Thomsen P and Moos T: The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson’s disease. Neuroscience. 95:425–432. 2000.PubMed/NCBI

Hunot S, Vila M, Teismann P, et al: JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson’s disease. Proc Natl Acad Sci USA. 101:665–670. 2004.PubMed/NCBI

Arimoto T and Bing G: Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis. 12:35–45. 2003. View Article : Google Scholar

Bartosz G: Peroxynitrite: mediator of the toxic action of nitric oxide. Acta Biochim Pol. 43:645–659. 1996.PubMed/NCBI

Orr CF, Rowe DB and Halliday GM: An inflammatory review of Parkinson’s disease. Prog Neurobiol. 68:325–340. 2002.

Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S and Jenner P: The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci. 22:317–330. 2005. View Article : Google Scholar

McLaughlin P, Zhou Y, Ma T, et al: Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia. 53:567–582. 2006. View Article : Google Scholar : PubMed/NCBI

Wersinger C and Sidhu A: An inflammatory pathomechanism for Parkinson’s disease? Curr Med Chem. 13:591–602. 2006.

Stoll G, Jander S and Schroeter M: Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J Neural Transm Suppl. 59:81–89. 2000.PubMed/NCBI

Wang DD and Bordey A: The astrocyte odyssey. Prog Neurobiol. 86:342–367. 2008.

Vila M, Jackson-Lewis V, Guégan C, et al: The role of glial cells in Parkinson’s disease. Curr Opin Neurol. 14:483–489. 2001.

Ortinski PI, Dong J, Mungenast A, et al: Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat Neurosci. 13:584–591. 2010. View Article : Google Scholar : PubMed/NCBI

Mythri RB, Venkateshappa C, Harish G, et al: Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson’s disease brains. Neurochem Res. 36:1452–1463. 2011.PubMed/NCBI

Aoki E, Yano R, Yokoyama H, Kato H and Araki T: Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol. 86:57–64. 2009. View Article : Google Scholar : PubMed/NCBI

Saura J, Parés M, Bové J, et al: Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity. J Neurochem. 85:651–661. 2003. View Article : Google Scholar : PubMed/NCBI

Bélanger M and Magistretti PJ: The role of astroglia in neuroprotection. Dialogues Clin Neurosci. 11:281–295. 2009.

Sortwell CE, Daley BF, Pitzer MR, McGuire SO, Sladek JR Jr and Collier TJ: Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death. J Comp Neurol. 426:143–153. 2000. View Article : Google Scholar

Dong Y and Benveniste EN: Immune function of astrocytes. Glia. 36:180–190. 2001. View Article : Google Scholar : PubMed/NCBI

Wang Q, Tang XN and Yenari MA: The inflammatory response in stroke. J Neuroimmunol. 184:53–68. 2007. View Article : Google Scholar

Gomide V, Bibancos T and Chadi G: Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools. Int J Neurosci. 115:557–582. 2005. View Article : Google Scholar

Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H and Takahashi H: NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains. Acta Neuropathol. 99:14–20. 2000.PubMed/NCBI

Benarroch EE: Oligodendrocytes: Susceptibility to injury and involvement in neurologic disease. Neurology. 72:1779–1785. 2009. View Article : Google Scholar : PubMed/NCBI

Khan O, Filippi M, Freedman MS, et al: Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol. 67:286–290. 2010. View Article : Google Scholar : PubMed/NCBI

Takagi S, Hayakawa N, Kimoto H, Kato H and Araki T: Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm. 114:1553–1557. 2007. View Article : Google Scholar : PubMed/NCBI

Rosin C, Colombo S, Calver AA, Bates TE and Skaper SD: Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia. 52:336–343. 2005. View Article : Google Scholar

McTigue DM and Tripathi RB: The life, death, and replacement of oligodendrocytes in the adult CNS. J Neurochem. 107:1–19. 2008. View Article : Google Scholar : PubMed/NCBI

Kurkowska-Jastrzebska I, Bałkowiec-Iskra E, Ciesielska A, et al: Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson’s disease. Int Immunopharmacol. 9:781–791. 2009.

Zhao C, Ling Z, Newman MB, Bhatia A and Carvey PM: TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis. 26:36–46. 2007. View Article : Google Scholar : PubMed/NCBI

Pieper HC, Evert BO, Kaut O, Riederer PF, Waha A and Wüllner U: Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. Neurobiol Dis. 32:521–527. 2008. View Article : Google Scholar

Rousselet E, Callebert J, Parain K, et al: Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp Neurol. 177:183–192. 2002. View Article : Google Scholar : PubMed/NCBI

Boka G, Anglade P, Wallach D, Javoy-Agid, et al: Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett. 172:151–154. 1994.PubMed/NCBI

Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI and O’Callaghan JP: Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J. 20:670–682. 2006. View Article : Google Scholar : PubMed/NCBI

Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI and O’Callaghan JP: Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease. FASEB J. 16:1474–1476. 2002.PubMed/NCBI

McCoy MK, Martinez TN, Ruhn KA, et al: Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci. 26:9365–9375. 2006.

Scalzo P, Kümmer A, Cardoso F and Teixeira AL: Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neurosci Lett. 468:56–58. 2010.PubMed/NCBI

Wu DC, Jackson-Lewis V, Vila M, et al: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 22:1763–1771. 2002.PubMed/NCBI

Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM and Pitossi FJ: Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis. 24:183–193. 2006. View Article : Google Scholar : PubMed/NCBI

Machado A, Herrera AJ, Venero JL, et al: inflammatory animal model for Parkinson’s disease: the intranigral injection of lps induced the inflammatory process along with the selective degeneration of nigrostriatal dopaminergic neurons. ISRN Neurol. 2011:4761582011.

Sawada M, Imamura K and Nagatsu T: Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl. 70:373–381. 2006.

Nagatsu T and Sawada M: Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des. 11:999–1016. 2005.

Mount MP, Lira A, Grimes D, et al: Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci. 27:3328–3337. 2007. View Article : Google Scholar : PubMed/NCBI

Litteljohn D, Mangano E, Shukla N and Hayley S: Interferon-gamma deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience. 164:1894–1906. 2009. View Article : Google Scholar

Mogi M, Kondo T, Mizuno Y and Nagatsu T: p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett. 414:94–97. 2007. View Article : Google Scholar : PubMed/NCBI

Chen H, O’Reilly EJ, Schwarzschild MA and Ascherio A: Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol. 167:90–95. 2008.

Gonzalez-Aparicio R, Flores JA and Fernandez-Espejo EE: Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor beta1 is enhanced after co-infusion in rats. Exp Neurol. 226:136–147. 2010. View Article : Google Scholar : PubMed/NCBI

Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G and Ferrero P: Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer’s disease patients. Neurol Sci. 27:33–39. 2006.

Rentzos M, Nikolaou C, Andreadou E, et al: Circulating interleukin-10 and interleukin-12 in Parkinson’s disease. Acta Neurol Scand. 119:332–337. 2009.PubMed/NCBI

Arimoto T, Choi DY, Lu X, et al: Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging. 28:894–906. 2007. View Article : Google Scholar : PubMed/NCBI

Qian L, Block ML, Wei SJ, et al: Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther. 319:44–52. 2006. View Article : Google Scholar

Sánchez-Capelo A, Colin P, Guibert B, Biguet NF and Mallet J: Transforming growth factor beta 1 overexpression in the nigrostriatal system increases the dopaminergic deficit of MPTP mice. Mol Cell Neurosci. 23:614–625. 2003.PubMed/NCBI

Qian L, Wei SJ, Zhang D, et al: Potent anti-inflammatory and neuroprotective effects of TGF-beta 1 are mediated through the inhibition of ERK and p47^PHOX-Ser³⁴⁵ phosphorylation and translocation in microglia. J Immunol. 181:660–668. 2008. View Article : Google Scholar : PubMed/NCBI

Ross OA, O’Neill C, Rea IM, et al: Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson’s disease in the Irish. Hum Immunol. 65:340–346. 2004.PubMed/NCBI

Nishimura M, Kuno S, Mizuta I, et al: Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson’s disease. Mov Disord. 18:953–955. 2003.PubMed/NCBI

Shimoji M, Pagan F, Healton EB and Mocchetti I: CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson’s disease. Neurotox Res. 16:318–328. 2009.PubMed/NCBI

Edman LC, Mira H, Erices A, et al: Alpha-chemokines regulate proliferation, neurogenesis, and dopaminergic differentiation of ventral midbrain precursors and neurospheres. Stem Cells. 26:1891–1900. 2008. View Article : Google Scholar

Tsai SJ, Chao CY and Yin MC: Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice. Eur J Pharmacol. 670:441–447. 2011. View Article : Google Scholar : PubMed/NCBI

Wang Q, Zheng H, Zhang ZF and Zhang YX: Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra of mice with MPTP-induced Parkinson disease through the P38 signaling pathway. Nan Fang Yi Ke Da Xue Xue Bao. 28:1594–1598. 2008.(In Chinese).

Wang Y, Zhang Y, Wei Z, Li H, Zhou H and Zhang Z and Zhang Z: JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson’s disease. J Neurol Sci. 285:172–177. 2009.PubMed/NCBI

Gupta A, Dhir A, Kumar A and Kulkarni SK: Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats. Pharmacol Biochem Behav. 94:219–226. 2009. View Article : Google Scholar : PubMed/NCBI

Moghaddam HF, Hemmati A, Nazari Z, Mehrab H, Abid KM and Ardestani MS: Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson’s disease. Pak J Biol Sci. 10:3853–3858. 2007.PubMed/NCBI

Litteljohn D, Mangano EN and Hayley S: Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. Eur J Neurosci. 28:707–716. 2008. View Article : Google Scholar : PubMed/NCBI

Hoang T, Choi DK, Nagai M, et al: Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radic Biol Med. 47:1049–1056. 2009. View Article : Google Scholar : PubMed/NCBI

McClain JA, Phillips LL and Fillmore HL: Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration. Neurosci Lett. 460:27–31. 2009. View Article : Google Scholar

Kim EM and Hwang O: Role of matrix metalloproteinase-3 in neurodegeneration. J Neurochem. 116:22–32. 2011. View Article : Google Scholar : PubMed/NCBI

Shin EJ, Kim EM, Lee JA, Rhim H and Hwang O: Matrix metalloproteinase-3 is activated by HtrA2/Omi in dopaminergic cells: relevance to Parkinson’s disease. Neurochem Int. 60:249–256. 2012.PubMed/NCBI

Kim YS, Kim SS, Cho JJ, et al: Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci. 25:3701–3711. 2005. View Article : Google Scholar : PubMed/NCBI

Choi DH, Kim YJ, Kim YG, Joh TH, Beal MF and Kim YS: Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. J Biol Chem. 286:14168–14177. 2011. View Article : Google Scholar : PubMed/NCBI

Kim YS, Choi DH, Block ML, et al: A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J. 21:179–187. 2007. View Article : Google Scholar : PubMed/NCBI

Choi DH, Kim EM, Son HJ, et al: A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J Neurochem. 106:405–415. 2008. View Article : Google Scholar : PubMed/NCBI

Lorenzl S, Albers DS, Narr S, Chirichigno J and Beal MF: Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson’s disease. Exp Neurol. 178:13–20. 2002.PubMed/NCBI

Lorenzl S, Calingasan N, Yang L, et al: Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuromolecular Med. 5:119–132. 2004. View Article : Google Scholar : PubMed/NCBI

Nomura N, Miyajima N, Sazuka T, et al: Prediction of the coding sequences of unidentified human genes. I The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1 (supplement). DNA Res. 1:47–56. 1994. View Article : Google Scholar

Tabeta K, Georgel P, Janssen E, et al: Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA. 101:3516–3521. 2004. View Article : Google Scholar : PubMed/NCBI

Atkinson TJ: Toll-like receptors, transduction-effector pathways, and disease diversity: evidence of an immunobiological paradigm explaining all human illness? Int Rev Immunol. 27:255–281. 2008. View Article : Google Scholar

Bsibsi M, Ravid R, Gveric D and van Noort JM: Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol. 61:1013–1021. 2002.PubMed/NCBI

Lehnardt S, Massillon L, Follett P, et al: Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA. 100:8514–8519. 2003. View Article : Google Scholar : PubMed/NCBI

Panaro MA, Lofrumento DD, Saponaro C, et al: Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson’s-like disease. Immunopharmacol Immunotoxicol. 30:729–740. 2008.PubMed/NCBI

Noelker C, Morel L, Lescot T, et al: Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep. 3:13932013. View Article : Google Scholar : PubMed/NCBI

Kim C, Ho DH, Suk JE, et al: Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 4:15622013.PubMed/NCBI

Letiembre M, Liu Y, Walter S, et al: Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging. 30:759–768. 2009. View Article : Google Scholar : PubMed/NCBI

Groemping Y and Rittinger K: Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J. 386:401–416. 2005. View Article : Google Scholar : PubMed/NCBI

Babior BM: NADPH oxidase: an update. Blood. 93:1464–1476. 1999.PubMed/NCBI

Anantharam V, Kaul S, Song C, Kanthasamy A and Kanthasamy AG: Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology. 28:988–997. 2007. View Article : Google Scholar

Cristóvão AC, Choi DH, Baltazar G, Beal MF and Kim YS: The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid Redox Signal. 11:2105–2118. 2009.PubMed/NCBI

Wu DC, Teismann P, Tieu K, et al: NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci USA. 100:6145–6150. 2003.

Liangliang X, Yonghui H, Shunmei E, Shoufang G, Wei Z and Jiangying Z: Dominant-positive HSF1 decreases alpha-synuclein level and alpha-synuclein-induced toxicity. Mol Biol Rep. 37:1875–1881. 2010. View Article : Google Scholar : PubMed/NCBI

Benn SC and Woolf CJ: Adult neuron survival strategies - slamming on the brakes. Nat Rev Neurosci. 5:686–700. 2004. View Article : Google Scholar : PubMed/NCBI

Meriin AB and Sherman MY: Role of molecular chaperones in neurodegenerative disorders. Int J Hyperthermia. 21:403–419. 2005. View Article : Google Scholar : PubMed/NCBI

Auluck PK, Chan HY, Trojanowski JQ, Lee VM and Bonini NM: Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science. 295:865–868. 2002.PubMed/NCBI

Tantucci M, Mariucci G, Taha E, et al: Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment. Neuroscience. 163:735–740. 2009. View Article : Google Scholar : PubMed/NCBI

Pan T, Li X, Xie W, Jankovic J and Le W: Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 579:6716–6720. 2005. View Article : Google Scholar : PubMed/NCBI

Shen HY, He JC, Wang Y, Huang QY and Chen JF: Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem. 280:39962–39969. 2005. View Article : Google Scholar : PubMed/NCBI

Dedmon MM, Christodoulou J, Wilson MR and Dobson CM: Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem. 280:14733–14740. 2005. View Article : Google Scholar : PubMed/NCBI

Liu M, Aneja R, Sun X, et al: Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase. J Biol Chem. 283:35783–35788. 2008. View Article : Google Scholar : PubMed/NCBI

Uryu K, Richter-Landsberg C, Welch W, et al: Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am J Pathol. 168:947–961. 2006. View Article : Google Scholar : PubMed/NCBI

Calabrese V, Mancuso C, Ravagna A, et al: In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. J Neurochem. 101:709–717. 2007. View Article : Google Scholar

Kulathingal J, Ko LW, Cusack B and Yen SH: Proteomic profiling of phosphoproteins and glycoproteins responsive to wild-type alpha-synuclein accumulation and aggregation. Biochim Biophys Acta. 1794:211–224. 2009. View Article : Google Scholar : PubMed/NCBI

Wang L, Xie C, Greggio E, et al: The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci. 28:3384–3391. 2008. View Article : Google Scholar : PubMed/NCBI

Liu J, Zhang JP, Shi M, et al: Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci. 29:1480–1485. 2009. View Article : Google Scholar : PubMed/NCBI

Cassarino DS, Halvorsen EM, Swerdlow RH, et al: Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson’s disease. J Neurochem. 74:1384–1392. 2000.PubMed/NCBI

Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L and Lucius R: Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson’s disease. FASEB J. 17:500–502. 2003.PubMed/NCBI

Yang HJ, Wang L, Xia YY, Chang PN and Feng ZW: NF-kappaB mediates MPP+ induced apoptotic cell death in neuroblastoma cells SH-EP1 through JNK and c-Jun/AP-1. Neurochem Int. 56:128–134. 2010. View Article : Google Scholar : PubMed/NCBI

Panet H, Barzilai A, Daily D, Melamed E and Offen D: Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J Neurochem. 77:391–398. 2001. View Article : Google Scholar : PubMed/NCBI

Wang X, Qin ZH, Leng Y, et al: Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells. J Neurochem. 83:1094–1102. 2002. View Article : Google Scholar : PubMed/NCBI

Weingarten P, Bermak J and Zhou QY: Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-kappa B and lack of protection by anti-oxidants. J Neurochem. 76:1794–1804. 2001. View Article : Google Scholar : PubMed/NCBI

Kenchappa RS and Ravindranath V: Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP. FASEB J. 17:717–719. 2003.PubMed/NCBI

Liang ZQ, Li YL, Zhao XL, et al: NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res. 1145:190–203. 2007. View Article : Google Scholar : PubMed/NCBI

Williams CA, Lin Y, Maynard A and Cheng SY: Involvement of NF kappa B in potentiated effect of mn-containing dithiocarbamates on MPP(+) induced cell death. Cell Mol Neurobiol. 33:815–823. 2013. View Article : Google Scholar : PubMed/NCBI

Pranski E, Van Sanford CD, Dalal N, et al: NF-κB activity is inversely correlated to RNF11 expression in Parkinson’s disease. Neurosci Lett. 547:16–20. 2013.

Dehmer T, Heneka MT, Sastre M, Dichgans J and Schulz JB: Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem. 88:494–501. 2004.PubMed/NCBI

Ghosh A, Roy A, Liu X, et al: Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. Proc Natl Acad Sci USA. 104:18754–18759. 2007.PubMed/NCBI

Soós J, Engelhardt JI, Siklós L, Havas L and Majtényi K: The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. Neuroreport. 15:1715–1718. 2004.PubMed/NCBI

Cao JP, Wang HJ, Yu JK, Liu HM and Gao DS: The involvement of NF-kappaB p65/p52 in the effects of GDNF on DA neurons in early PD rats. Brain Res Bull. 76:505–511. 2008. View Article : Google Scholar : PubMed/NCBI

Wang J, Du XX, Jiang H and Xie JX: Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells. Biochem Pharmacol. 78:178–183. 2009. View Article : Google Scholar : PubMed/NCBI

Bonifati V, Rizzu P, Squitieri F, et al: DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci. 24:159–160. 2003. View Article : Google Scholar : PubMed/NCBI

Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K and Ariga H: DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5:213–218. 2004. View Article : Google Scholar : PubMed/NCBI

Inden M, Taira T, Kitamura Y, et al: PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson’s disease rat model. Neurobiol Dis. 24:144–158. 2006.PubMed/NCBI

Yanagida T, Takata K, Inden M, et al: Distribution of DJ-1, Parkinson’s disease-related protein PARK7, and its alteration in 6-hydroxydopamine-treated hemiparkinsonian rat brain. J Pharmacol Sci. 102:243–247. 2006.

Yanagisawa D, Kitamura Y, Inden M, et al: DJ-1 protects against neurodegeneration caused by focal cerebral ischemia and reperfusion in rats. J Cereb Blood Flow Metab. 28:563–578. 2008. View Article : Google Scholar : PubMed/NCBI

Zhou W and Freed CR: DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem. 280:43150–43158. 2005. View Article : Google Scholar : PubMed/NCBI

Lavara-Culebras E and Paricio N: Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. Gene. 400:158–165. 2007. View Article : Google Scholar : PubMed/NCBI

Andres-Mateos E, Perier C, Zhang L, et al: DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA. 104:14807–14812. 2007. View Article : Google Scholar

Goldberg MS, Pisani A, Haburcak M, et al: Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron. 45:489–496. 2005. View Article : Google Scholar

Kim RH, Smith PD, Aleyasin H, et al: Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA. 102:5215–5220. 2005. View Article : Google Scholar

Chen L, Cagniard B, Mathews T, et al: Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem. 280:21418–21426. 2005. View Article : Google Scholar

Yamaguchi H and Shen J: Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice. Mol Neurodegener. 2:102007. View Article : Google Scholar : PubMed/NCBI

Waak J, Weber SS, Görner K, et al: Oxidizable residues mediating protein stability and cytoprotective interaction of DJ-1 with apoptosis signal-regulating kinase 1. J Biol Chem. 284:14245–14257. 2009. View Article : Google Scholar

Chandran JS, Lin X, Zapata A, et al: Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. Neurobiol Dis. 29:505–514. 2008. View Article : Google Scholar

Mullett SJ, Hamilton RL and Hinkle DA: DJ-1 immunoreactivity in human brain astrocytes is dependent on infarct presence and infarct age. Neuropathology. 29:125–131. 2009. View Article : Google Scholar : PubMed/NCBI

Mullett SJ and Hinkle DA: DJ-1 knock-down in astrocytes impairs astrocyte-mediated neuroprotection against rotenone. Neurobiol Dis. 33:28–36. 2009. View Article : Google Scholar : PubMed/NCBI

Kang WY, Yang Q, Jiang XF, et al: Salivary DJ-1 could be an indicator of Parkinson’s disease progression. Front Aging Neurosci. 6:1022014.PubMed/NCBI

Shadrach KG, Rayborn ME, Hollyfield JG and Bonilha VL: DJ-1-dependent regulation of oxidative stress in the retinal pigment epithelium (RPE). PLoS One. 8:e679832013. View Article : Google Scholar : PubMed/NCBI

Liu F, Nguyen JL, Hulleman JD, Li L and Rochet JC: Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson’s disease. J Neurochem. 105:2435–2453. 2008.PubMed/NCBI

Neumann M, Müller V, Görner K, Kretzschmar HA, Haass C and Kahle PJ: Pathological properties of the Parkinson’s disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease. Acta Neuropathol. 107:489–496. 2004.

Waragai M, Wei J, Fujita M, et al: Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease. Biochem Biophys Res Commun. 345:967–972. 2006.PubMed/NCBI

Kumaran R, Vandrovcova J, Luk C, et al: Differential DJ-1 gene expression in Parkinson’s disease. Neurobiol Dis. 36:393–400. 2009.

Nural H, He P, Beach T, Sue L, Xia W and Shen Y: Dissembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson’s disease patients. Mol Neurodegener. 4:232009.

Xie Z, Zhuang X and Chen L: DJ-1 mRNA anatomical localization and cell type identification in the mouse brain. Neurosci Lett. 465:214–219. 2009. View Article : Google Scholar : PubMed/NCBI

Lev N, Roncevic D, Ickowicz D, Melamed E and Offen D: Role of DJ-1 in Parkinson’s disease. J Mol Neurosci. 29:215–225. 2006.

Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E and Offen D: DJ-1 protects against dopamine toxicity. J Neural Transm. 116:151–160. 2009. View Article : Google Scholar : PubMed/NCBI

Pei L, Castrillo A and Tontonoz P: Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Mol Endocrinol. 20:786–794. 2006. View Article : Google Scholar : PubMed/NCBI

Doi Y, Oki S, Ozawa T, Hohjoh H, Miyake S and Yamamura T: Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines. Proc Natl Acad Sci USA. 105:8381–8386. 2008. View Article : Google Scholar : PubMed/NCBI

Pei L, Castrillo A, Chen M, Hoffmann A and Tontonoz P: Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J Biol Chem. 280:29256–29262. 2005. View Article : Google Scholar : PubMed/NCBI

Maheux J, Ethier I, Rouillard C and Lévesque D: Induction patterns of transcription factors of the nur family (nurr1, nur77, and nor-1) by typical and atypical antipsychotics in the mouse brain: implication for their mechanism of action. J Pharmacol Exp Ther. 313:460–473. 2005. View Article : Google Scholar

Gilbert F, Morissette M, St-Hilaire M, et al: Nur77 gene knockout alters dopamine neuron biochemical activity and dopamine turnover. Biol Psychiatry. 60:538–547. 2006. View Article : Google Scholar : PubMed/NCBI

Jankovic J, Chen S and Le WD: The role of Nurr1 in the development of dopaminergic neurons and Parkinson’s disease. Prog Neurobiol. 77:128–138. 2005.

Pan T, Zhu W, Zhao H, et al: Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 1222:222–229. 2008. View Article : Google Scholar : PubMed/NCBI

Fan X, Luo G, Ming M, et al: Nurr1 expression and its modulation in microglia. Neuroimmunomodulation. 16:162–170. 2009. View Article : Google Scholar : PubMed/NCBI

Bensinger SJ and Tontonoz P: A Nurr1 pathway for neuroprotection. Cell. 137:26–28. 2009. View Article : Google Scholar : PubMed/NCBI